Skip to content

Rigel Pharmaceuticals RIGL Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
25M0.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
10M
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
10M0.0%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
5M0.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's convertible preferred stock authorized shares?
Rigel Pharmaceuticals (RIGL) reported convertible preferred stock authorized shares of 10M in Q4 2025.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.